Acadia Pharmaceuticals Posts Strong Q2 2026 Growth on DAYBUE and NUPLAZID Momentum — Acadia Pharmaceuticals Inc.

Event summary

Acadia Pharmaceuticals reported a 17% year-over-year revenue growth in Q2 2026, driven by strong performance of DAYBUE and NUPLAZID.
DAYBUE sales increased by 30% compared to the same period last year, while NUPLAZID saw a 9% rise.
The company completed enrollment in the Phase 2 portion of the RADIANT program for remlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening.
FDA granted Fast Track designation for remlifanserin, recognizing its potential to address Alzheimer's disease psychosis.
EMA's CHMP adopted a positive opinion recommending marketing authorization for DAYBU in the EU for Rett syndrome.

The big picture

Acadia Pharmaceuticals' Q2 2026 results highlight the company's strong commercial execution in its core products, DAYBUE and NUPLAZID. The strategic focus on expanding into new therapeutic areas, such as Alzheimer's disease psychosis with remlifanserin, positions Acadia to address significant unmet medical needs. The positive regulatory developments in both the U.S. and Europe further bolster the company's growth prospects.

What we're watching

Clinical Milestones: The anticipated topline results from the Phase 2 program evaluating remlifanserin in Alzheimer's disease psychosis could represent a transformational opportunity for Acadia.
Regulatory Progress: Whether DAYBU will secure marketing authorization from the European Commission following the positive opinion from EMA's CHMP.
Commercial Execution: The pace at which Acadia can sustain the strong momentum in both DAYBUE and NUPLAZID sales to meet its long-term ambition of $1.7 billion in annual net sales by 2028.